Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges with weekly injections and conservative doctor prescribing habits as key hurdles. The advent of oral alternatives might boost uptake, suggesting convenience and long-term commitment, rather than price, will drive future acceptance of these weight-loss therapies in India.